Azaya therapeutics outlicenses rights to liposomal docetaxel (AT1123) to Beijing’s CANbridge Lifescience

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. Financial details of the arrangement were not disclosed. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

China based CANbridge life sciences has acquired exclusive development and commercialization rights to Azaya therapeutics lung cancer drug candidiate ATI-1123 for China south korea and Taiwan.

ATI-1123, is a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation.

As part of the agreement, CANbridge, which is based in Beijing, China, will fund clinical development in China and North Asia, collaborating with Azaya on clinical trial design.

Financial terms of the deal have not been disclosed.

“Our commercialization strategy for ATI-1123 is to seek approval in the United States and European Union, primarily. However, the CANbridge opportunity was presented and we felt it was too good to pass up,” says Azaya President and CEO Mike Dwyer. “The people who comprise the CANbridge team were responsible for Chinese regulatory approval of several leading Genzyme products. We know them personally and know they only take on drugs they believe will suit their market. We have a high degree of trust in their ability to get the job done.”

CANbridge Life Sciences founder James Xue was previously the general manager of Genzyme China. As such, the Azaya team was confident in his work.

Enter your email address: Delivered by FeedBurner